Former FDA head says biotech business model 'is basically falling apart' (Boston Business Journal)
A former head of the U.S. Food and Drug Administration who will help lead a discussion at Tufts University today says that the agency is holding back, rather than encouraging, the creation of groundbreaking new drugs.
Andrew von Eschenbach, commissioner of the FDA for more than two years until January 2009, said in an interview Friday that as a result of FDA demands, drug trials have become too large and expensive. He said the FDA has become too “risk-averse” at a time when scientists in the phar...
Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.
Hit the SUBSCRIBE button at the top of the homepage.